The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer
Both intermediate- and high-risk prostate cancer patients with an interval from biopsy to RP >3-≤6 months did not differ from those treated with RP ≤3 months after biopsy, regarding adverse histopathological outcomes and BCR rates. Therefore, it might be safe to postpone RP up to six months.
Authors
- Felix K.‐H. Chun (ORCID: https://orcid.org/0000-0001-8486-9536)
- Carolin Siech (ORCID: https://orcid.org/0000-0002-5460-4171)
- Luis A. Kluth (ORCID: https://orcid.org/0000-0002-4629-4388)
- Miriam I. Traumann
- Felix Preißer (ORCID: https://orcid.org/0000-0002-7382-9632)
- Clara Humke
- Philipp Mandel (ORCID: https://orcid.org/0000-0002-0760-7281)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Cristina Cano Garcia (ORCID: https://orcid.org/0000-0002-4829-0241)
- Georgina Knoblich
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.3389/fonc.2024.1533800
- Citations
- 3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56